The interaction between aspirin and losartan on cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. A losartan intervention for endpoint reduction (LIFE) substudy

被引：0
|
作者：
Fossum, E
Kjeldsen, SE
Dahlof, B
Devereux, RB
Julius, S
Snapinn, S
机构：
[1] Ullevaal Univ Hosp, Dept Cardiol, Oslo, Norway
[2] Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden
[3] Cornell Med Ctr, Div Cardiol, New York, NY USA
[4] Univ Michigan, Dept Internal Med, Div Hypertens, Ann Arbor, MI 48109 USA
[5] Merck & Co Inc, Whitehouse Stn, NJ USA
来源：
AMERICAN JOURNAL OF HYPERTENSION | 2003年 / 16卷 / 05期
关键词：
losartan; aspirin; atenolol;
D O I：
10.1016/S0895-7061(03)00111-0
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
OR27
引用
收藏
页码：11A / 12A
页数：2
相关论文
共 50 条
  • [31] Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy
    Olsen, MH
    Wachtell, K
    Tuxen, C
    Fossum, E
    Bang, LE
    Hall, C
    Ibsen, H
    Rokkedal, J
    Devereux, RB
    Hildebrandt, PR
    JOURNAL OF HYPERTENSION, 2005, 23 (05) : 1083 - 1090
  • [32] Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study
    Larstorp, Anne Cecilie K.
    Ariansen, Inger
    Gjesdal, Knut
    Olsen, Michael H.
    Ibsen, Hans
    Devereux, Richard B.
    Okin, Peter M.
    Dahlof, Bjorn
    Kjeldsen, Sverre E.
    Wachtell, Kristian
    HYPERTENSION, 2012, 60 (02) : 347 - +
  • [33] The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study
    M H Olsen
    K Wachtell
    B Dahlöf
    R B Devereux
    H Ibsen
    S E Kjeldsen
    L H Lindholm
    P A Lyle
    M S Nieminen
    Journal of Human Hypertension, 2006, 20 : 460 - 464
  • [34] Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study
    Kizer, JR
    Hoieggen, A
    Alderman, MH
    Kjeldsen, SE
    Dahlof, B
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Oparil, S
    Wedel, H
    Edelman, JM
    Snapinn, SM
    Devereux, RB
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 475A - 475A
  • [35] Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy?: A LIFE substudy
    Ibsen, H
    Wachtell, K
    Olsen, MH
    Borch-Johnsen, K
    Lindholm, LH
    Mogensen, CE
    Dahlöf, B
    Devereux, RB
    de Faire, U
    Fyhrquist, F
    Julius, S
    Kjeldsen, SE
    Lederballe-Pedersen, O
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wan, Y
    JOURNAL OF HYPERTENSION, 2004, 22 (09) : 1805 - 1811
  • [36] The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study
    Olsen, MH
    Wachtell, K
    Dahlof, B
    Devereux, RB
    Ibsen, H
    Kjeldsen, SE
    Lindholm, LH
    Lyle, PA
    JOURNAL OF HUMAN HYPERTENSION, 2006, 20 (06) : 460 - 464
  • [37] Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The losartan intervention for endpoint reduction in hypertension (LIFE) Trial - Letter regarding article by Devereux et al.
    O'Rourke, MF
    Safar, ME
    CIRCULATION, 2005, 111 (22) : E377 - E377
  • [38] Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left-ventricular hypertrophy. A LIFE Study
    Olsen, MH
    Wachtell, K
    Tuxen, C
    Fossum, E
    Hall, C
    Ibsen, H
    Devereux, RB
    Hildebrandt, P
    EUROPEAN HEART JOURNAL, 2003, 24 : 580 - 580
  • [39] Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension -: A losartan intervention for endpoint-reduction in hypertension (LIFE) substudy
    Olsen, MH
    Wachtell, K
    Bella, JN
    Palmieri, V
    Gerdts, E
    Smith, G
    Nieminen, MS
    Dahlöf, B
    Ibsen, H
    Devereux, RB
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (11) : 1430 - 1436
  • [40] Albuminuria predicts cardiovascular outcome on treatment with losartan versus atenolol in patients with diabetes, hypertension and left ventricular hypertrophy?: A life diabetes substudy
    Ibsen, H
    Olsen, MH
    Wachtell, K
    Borch-Johnsen, K
    Lindholm, L
    Dahlöf, B
    Snapinn, S
    JOURNAL OF HYPERTENSION, 2004, 22 : S64 - S64
12345